The induction of oxidative/nitrosative stress, inflammation, and apoptosis by a ferric carboxymaltose copy compared to iron sucrose in a non-clinical model

Journal of Clinical and Diagnostic Research

Volumn 9, Issue 12, 2015, Pages FF08-FF12

  Toblli, Jorge E ^a   Cao, Gabriel ^a   Angerosa, Margarita ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Intravenous iron; Iron deficiency; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; CREATININE; FERRIC CARBOXYMALTOSE; GLUTATHIONE; HEMOGLOBIN; IRON; IRON SACCHARATE; TRANSFERRIN;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; GEL PERMEATION CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; IRON BLOOD LEVEL; IRON INTAKE; KIDNEY FUNCTION; LIVER FUNCTION; MICROSCOPY; MORPHOMETRICS; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PROTEINURIA; RAT;

EID: 84949232351     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2015/14266.6992     Document Type: Article

References (28)

1. de Benoist B, McLean E, Egli I, Cogswell M. Worldwide prevalence of anaemia 1993-2005: WHO global database on anaemia. Geneva, Switzerland: World Health Organisation; 2008.
2. Bailie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant. 2005;20(7):1443-49.
3. Koskenkorva-Frank TS, Weiss G, Koppenol WH, Burckhardt S. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radic Biol Med. 2013;65C:1174-94.
4. Funk F, Ryle P, Canclini C, Neiser S, Geisser P. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose. Drug Res. 2010;60(6):345-53.
5. Jahn MR, Andreasen HB, Fütterer S, Nawroth T, Schünemann V, Kolb U, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011;78(3):480-91.
6. Bregman DB, Goodnough LT. Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia. Ther Adv Hematol. 2014;5(2):48-60.
7. Neiser S, Wilhelm M, Schwarz K, Funk F, Geisser P, Burckhardt S. Assessment of dextran antigenicity of intravenous iron products by immunodiffusion assay. Port J Nephrol Hypert. 2011;25(3):219-24.
8. Beshara S, Sorensen J, Lubberink M, Tolmachev V, Langstrom B, Antoni G, et al. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol. 2003;120(5):853-59.
9. Cada DJ, Levien TL, Baker DE. Ferric carboxymaltose. Hosp Pharm. 2014;49(1):52-69.
10. Toblli JE, Cao G, Olivieri L, Angerosa M. Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds. Nephrol Dial Transplant. 2010;25(11):3631-40.
11. Toblli JE, Cao G, Oliveri L, Angerosa M. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model. Drug Res. 2010;61(7):399-410.
12. Toblli JE, Cao G, Giani JF, Dominici FP, Angerosa M. Nitrosative stress and apoptosis by intravenous ferumoxytol, iron isomaltoside 1000, iron dextran, iron sucrose, and ferric carboxymaltose in a nonclinical model. Drug Res. 2014;64:1-7.
13. Ehmann F, Sakai-Kato K, Duncan R, Pérez de la Ossa DH, Pita R, Vidal JM, et al. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. Nanomedicine. 2013;8(5):849-56.
14. Schellekens H, Stegemann S, Weinstein V, de Vlieger JS, Fluhmann B, Muhlebach S, et al. How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider. AAPS J. 2014;16(1):15-21.
15. European Medicines Agency (EMA). Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product. London, UK: European Medicines Agency; 2015. Report No.: EMA/CHMP/SWP/620008/2012.
16. Toblli JE, Cao G, Oliveri L, Angerosa M. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflamm Allergy Drug Targets. 2012;11(1):66-78.
17. Toblli JE, Cao G, Angerosa M. Nitrosative stress and apoptosis in non-anemic healthy rats induced by intravenous iron sucrose similars versus iron sucrose originator. BioMetals. 2015;28(2):279-92.
18. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Drug Res. 1992;42(12):1439-52.
19. FDA. Draft: Guidance on iron sucrose. Washington D.C., USA: FDA; 2013. Report No.: 2013-26570.
20. Myers BM, Prendergast FG, Holman R, Kuntz SM, LaRusso NF. Alterations in the structure, physicochemical properties, and pH of hepatocyte lysosomes in experimental iron overload. J Clin Invest. 1991;88(4):1207-15.
21. Adams ET, Schwartz KA. Iron-induced myocardial and hepatic lysosomal abnormalities in the guinea pig. Toxicol Pathol. 1993;21(3):321-26.
22. Dimitriou E, Kairis M, Sarafidou J, Michelakakis H. Iron overload and kidney lysosomes. Biochim Biophys Acta. 2000;1501(2):138-48.
23. Kurz T, Terman A, Gustafsson B, Brunk UT. Lysosomes in iron metabolism, ageing and apoptosis. Histochem Cell Biol. 2008;129(4):389-406.
24. Rottembourg J, Kadri A, Leonard E, Dansaert A, Lafuma A. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol Dial Transplant. 2011;26(10):3262-67.
25. Lee ES, Park BR, Kim JS, Choi GY, Lee JJ, Lee IS. Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients. Curr Med Res Opin. 2013;29(2):141-47.
26. Stein J, Dignass A, Chow KU. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr Med Res Opin. 2012;28(2):241-43.
27. Thanusubramanian H, Patil N, Shenoy S, Bairy KL, Sarma Y. Adverse reactions of ferric carboxymaltose. J Clin Diagn Res. 2014;8(10):HD01-02.
28. European Medicines Agency, New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/IV_iron_31/WC500151308.pdf . 13-9-2013. 18-9-2014.